News & Views
Cevec Pharmaceuticals Signs License Agreement with Yuhan Corporation of South Korea
Feb 14 2013
Cevec Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation, a leading manufacturer of pharmaceutical products based in Seoul, South Korea announced today the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilise Cevec’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.
CAP-T™ CAP® cells are immortalised cell lines for transient and stable protein production developed by Cevec. These non-tumour origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior protein yields in a shorter time frame than traditional methods.
“With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We’re very pleased that Yuhan has chosen our CAP and CAP-T expression systems as a pivotal platform to develop therapeutically relevant molecules. I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases “ stated Wolfgang Kintzel, CEO at Cevec.
Dr Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: “After evaluating CAP and CAP-T we are excited about the potential of Cevec’s CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan